Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azacitidine.

Jean-Pierre Issa1, Hagop Kantarjian

  • 1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA. jpissa@mdanderson.org

Nature Reviews. Drug Discovery
|June 21, 2005
PubMed
Summary
This summary is machine-generated.

Azacitidine is a novel DNA methylation inhibitor approved for myelodysplastic syndromes. This epigenetic therapy targets cancer

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to BCR-ABL inhibitors: issues for CML therapy.

Clinical lymphoma, myeloma & leukemia·2012
Same author

Nilotinib-associated vascular events.

Clinical lymphoma, myeloma & leukemia·2012
Same author

How I treat newly diagnosed chronic phase CML.

Blood·2012
Same author

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.

Cancer·2012
Same author

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.

Clinical lymphoma, myeloma & leukemia·2012
Same author

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Clinical lymphoma, myeloma & leukemia·2012
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
Same journal

Pulsatile FXR agonism.

Nature reviews. Drug discovery·2026
Same journal

CRISPR strategy tackles bacterial toxin.

Nature reviews. Drug discovery·2026
Same journal

Time to peak sales: how long is the climb?

Nature reviews. Drug discovery·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Myelodysplastic syndromes (MDS) are rare bone-marrow disorders.
  • Cancer cells exploit epigenetic gene silencing to promote malignancy.
  • Azacitidine offers a new therapeutic strategy for MDS.

Purpose of the Study:

  • To introduce Azacitidine as a treatment for myelodysplastic syndromes.
  • To highlight Azacitidine's mechanism as a DNA methylation inhibitor.
  • To emphasize its role in targeting epigenetic gene silencing in cancer.

Main Methods:

  • FDA approval process for Azacitidine.
  • Classification as an orphan-drug.
  • Mechanism of action as a DNA methylation inhibitor.

Related Experiment Videos

Main Results:

  • Azacitidine approved by US FDA in May 2004 for MDS treatment.
  • Designated as an orphan-drug, indicating its use for rare diseases.
  • Demonstrated efficacy in targeting epigenetic mechanisms in cancer.

Conclusions:

  • Azacitidine represents a significant advancement in MDS therapy.
  • It is a pioneering epigenetic agent targeting cancer's gene silencing mechanisms.
  • Its approval marks a milestone in treating rare bone-marrow disorders.